Hide metadata

dc.contributor.authorKharman-Biz, Amirhossein
dc.contributor.authorGao, Hui
dc.contributor.authorGhiasvand, Reza
dc.contributor.authorZhao, Chunyan
dc.contributor.authorZendehdel, Kazem
dc.contributor.authorDahlman-Wright, Karin
dc.date.accessioned2015-10-20T10:56:57Z
dc.date.available2015-10-20T10:56:57Z
dc.date.issued2013
dc.identifier.citationBMC Cancer. 2013 Sep 28;13(1):441
dc.identifier.urihttp://hdl.handle.net/10852/47217
dc.description.abstractBackground The activator protein-1 (AP-1) transcription factor is believed to be important in tumorigenesis and altered AP-1 activity was associated with cell transformation. We aimed to assess the potential role of AP-1 family members as novel biomarkers in breast cancer. Methods We studied the expression of AP-1 members at the mRNA level in 72 primary breast tumors and 37 adjacent non-tumor tissues and evaluated its correlation with clinicopathological parameters including estrogen receptor (ER), progesterone receptor (PR) and HER2/neu status. Expression levels of Ubiquitin C (UBC) were used for normalization. Protein expression of AP-1 members was assessed using Western blot analysis in a subset of tumors. We used student’s t-test, one-way ANOVA, logistic regression and Pearson’s correlation coefficient for statistical analyses. Results We found significant differences in the expression of AP-1 family members between tumor and adjacent non-tumor tissues for all AP-1 family members except Fos B. Fra-1, Fra-2, Jun-B and Jun-D mRNA levels were significantly higher in tumors compared to adjacent non-tumor tissues (p < 0.001), whilst c-Fos and c-Jun mRNA levels were significantly lower in tumors compared with adjacent non-tumor tissues (p < 0.001). In addition, Jun-B overexpression had outstanding discrimination ability to differentiate tumor tissues from adjacent non-tumor tissues as determined by ROC curve analysis. Moreover, Fra-1 was significantly overexpressed in the tumors biochemically classified as ERα negative (p = 0.012) and PR negative (p = 0.037). Interestingly, Fra-1 expression was significantly higher in triple-negative tumors compared with luminal carcinomas (p = 0.01). Conclusions Expression levels of Fra-1 and Jun-B might be possible biomarkers for prognosis of breast cancer.
dc.language.isoeng
dc.rightsKharman-Biz et al.; licensee BioMed Central Ltd.
dc.rightsAttribution 2.0 Generic
dc.rights.urihttp://creativecommons.org/licenses/by/2.0/
dc.titleExpression of activator protein-1 (AP-1) family members in breast cancer
dc.typeJournal article
dc.date.updated2015-10-20T10:56:58Z
dc.creator.authorKharman-Biz, Amirhossein
dc.creator.authorGao, Hui
dc.creator.authorGhiasvand, Reza
dc.creator.authorZhao, Chunyan
dc.creator.authorZendehdel, Kazem
dc.creator.authorDahlman-Wright, Karin
dc.identifier.doihttp://dx.doi.org/10.1186/1471-2407-13-441
dc.identifier.urnURN:NBN:no-51340
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/47217/1/12885_2013_Article_4091.pdf
dc.type.versionPublishedVersion
cristin.articleid441


Files in this item

Appears in the following Collection

Hide metadata

Attribution 2.0 Generic
This item's license is: Attribution 2.0 Generic